Claims for Patent: 6,989,146

Summary for Patent: 6,989,146

Title:	Stress proteins and peptides and methods of use thereof
Abstract:	Provided are HLA pan DR peptides and methods of using such peptides to modulate, block, or inhibit immune responses in treatment of immune-mediated diseases and conditions, such as inflammatory and autoimmune diseases, cancer, and microbial infections. The peptides and methods are useful diagnostically to screen peptide or peptide analogs that can inhibit the pathogenic immune response or upregulate an immune response against aberrant or invading cells, to monitor efficacy or therapeutic use and to identify other agents that may be effective to inhibit or modulate the immune response.
Inventor(s):	Albani; Salvatore (Encinitas, CA), Prakken; Berent J. (Pieter Saenredamstraat, NL)
Assignee:	The Regents of the University of California (Oakland, CA)
Application Number:	09/828,574
Patent Claims:	1. An isolated peptide having about 10 to 30 amino acid residues wherein at least 9 amino acid residues of the peptide consist of a sequence as set forth in SEQ ID NO: 18, SEQ ID NO: 20, or SEQ ID NO: 23. 2. An isolated peptide according to claim 1, wherein the peptide binds to HLADR1, DR4, and DR7. 3. An isolated peptide according to claim 1, wherein the amino acid sequence is selected from an amino acid sequence from human heat shock protein or a bacterial heat shock protein. 4. An isolated peptide according to claim 3, wherein the bacterial heat shock protein is a mycobacterial heat shock protein. 5. An isolated peptide having about 10 to 30 amino acid residues and having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 7, 8, and 9. 6. An isolated peptide according to claim 5, wherein the stress protein is a heat shock protein. 7. An isolated peptide according to claim 6, wherein the heat shock protein is a bacterial heat shock protein. 8. An isolated peptide according to claim 6, wherein the heat shock protein is a mycobacterium species heat shock protein. 9. An isolated peptide according to claim 8, wherein the mycobacteriurn species heat shock protein is hsp65. 10. An isolated peptide according to claim 6, wherein the heat shock protein is a mammalian heat shock protein. 11. An isolated peptide according to claim 10, wherein the mammalian heat shock protein is a human heat shock protein. 12. An isolated peptide according to claim 11, wherein the human heat shock protein is human hsp60. 13. An isolated peptide according to claim 1, wherein the peptide is about 15 to 20 amino acids in length. 14. An isolated peptide according to claim 1, wherein the peptide has one or more D-amino acid residues. 15. An isolated peptide according to claim 1, wherein the peptide is covalently linked to an adjuvant. 16. An isolated peptide according to claim 15, wherein the adjuvant is keyhole limpet hemocyanin, bovine serum albumin, human serum albumin, or isologous IgG. 17. A pharmaceutical composition comprising a peptide according to claim 1 in a pharmaceutically acceptable carrier. 18. A composition comprising a pharmaceutically acceptable carrier and an isolated peptide according to claim 1. 19. A composition according to claim 18, wherein the peptide binds to at least one molecule selected from the group consisting of HLADR1, DR4, and DR7. 20. A composition according to claim 18, wherein the isolated peptide has an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 6, 7, 8, and 9. 21. A composition according to claim 18, further comprising a biological response modifier. 22. A composition according to claim 21, wherein the biological response modifier is selected from the group consisting of a cytokine, a chemokine, a hormone, a steroid, and an interleukin. 23. A composition according to claim 22, wherein the biological response modifier is an interferon. 24. A composition according to claim 21, wherein the biological response modifier is selected from the group consisting of IL-1(.alpha. or .beta.), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, GM-CSF, M-CSF, G-CSF, LIF, LT, TGF-.beta., .gamma.-LFN, TNF-1, BCGF, CD2, and ICAM. 25. An isolated peptide according to claim 1 that is chemically synthesized. 26. An isolated peptide according to claim 1 that is produced by recombinant expression. 27. An isolated peptide according to claim 1 or 5 or that is glycosylated. 28. A composition according to claim 18 that is a liquid formulation. 29. A composition according to claim 18 that is a solid formulation. 30. An isolated peptide wherein the amino acid sequence of the peptide consists of the amino acid sequence as set forth in SEQ ID NO: 6. 31. A composition comprising a pharmaceutically acceptable carrier and an isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence as set forth in SEQ ID NO: 6. 32. An isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence as set forth in SEQ ID) NO: 2. 33. A composition comprising a pharmaceutically acceptable carrier and an isolated peptide according to claim 32. 34. An isolated peptide, wherein the amino acid sequence of the peptide consists of the anino acid sequence as set forth in SEQ ID NO: 3. 35. A composition comprising a pharmaceutically acceptable carrier and an isolated peptide according to claim 34. 36. An isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence as set forth in SEQ ID NO: 5. 37. A composition comprising a pharmaceutically acceptable carrier and an isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence as set forth in SEQ ID NO: 5. 38. An isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence as set forth in SEQ ID NO: 7. 39. A composition comprising a pharmaceutically acceptable carner and an isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence as set forth in SEQ ID NO: 7. 40. An isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence as set forth in SEQ ID NO: 8. 41. A composition comprising a pharmaceutically acceptable carrier and an isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence as set forth in SEQ ID NO: 8. 42. An isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence as set forth in SEQ ID NO: 9. 43. A composition comprising a pharmaceutically acceptable carrier and an isolated peptide, wherein the amino acid sequence of the peptide consists of the amino acid sequence as set forth in SEQ ID NO: 9.

Details for Patent 6,989,146

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2020-08-09
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2020-08-09
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2020-08-09
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2020-08-09
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2020-08-09
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2020-08-09